Reshma Rangwala

Reshma Rangwala, M.D., Ph.D., has more than a decade of experience in oncology and drug development. Prior to joining Aravive, she served as Vice President, Medical, at Genmab, where she led the clinical development program for the first-in-class antibody drug conjugate, tisotumab vedotin, and managed clinical strategy, protocol development, data monitoring, data analysis, study report authoring, and biologic licensing application preparations. Prior to that, she served as Executive Clinical Director at Merck & Co, where she was involved in all stages of clinical development of Keytruda, a humanized monoclonal antibody against programmed death 1 (PD-1), in non-small cell lung cancer and gynecologic malignancies. Dr. Rangwala received her B.S. in Biology from Duke University and her M.D. Ph.D. from the University of Cincinnati College of Medicine. She completed her internal medicine residency at Barnes Jewish Hospital in St. Louis, MO and her medical oncology fellowship at the Hospital of the University of Pennsylvania.